PartnerRe falls to non-life UW loss as adverse development hits specialty
PartnerRe reported a modest $18mn Covid-19 charge in its specialty segment that added to adverse prior-year development of $95mn and pushed the unit’s combined ratio for the first quarter from 116.0 percent to 121.1 percent.